Upregulation of lncRNA PTOV1‐AS1 in hepatocellular carcinoma contributes to disease progression and sorafenib resistance through regulating miR‐505
Journal of Biochemical and Molecular Toxicology · 2023
DOI: 10.1002/jbt.23437 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2023. Verfasst von Xiaobin Chi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, 900TH Hospital of Joint Logistics Support Force, Fuzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, RNA, Long Noncoding, MicroRNAs. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Special Cultivation Fund for Outstanding Youth of the 900TH Hospital of Joint Logistics Support Force, Fujian Natural Science Foundation Project (General).
Abstract (Originalsprache)
Increasing evidence has displayed the vital influence of lncRNA in tumorigenesis and chemoresistance of cancer treatment. This study investigated the function of lncRNA PTOV1‐AS1 in hepatocellular carcinoma (HCC) and its role in sorafenib resistance. The relative expression of lncRNA and miRNA was measured by RT‐qPCR. The cellular activities including cell proliferation and invasion were explored by CCK‐8 and Transwell assays. Bioinformatics analysis and dual‐luciferase reporter assay were used to predict the targeting miRNA of PTOV1‐AS1. The expression levels of PTOV1‐AS1 were higher in HCC tissues than that in the normal tissues and associated with patients' overall survival. Knockdown of PTOV1‐AS1 decreased cell proliferation rate and invasion number. After treatment with different concentrations of sorafenib, the sorafenib‐resistant hepatoma cells were conducted. PTOV1‐AS1 expression levels were increased in HepG2‐SR and Huh7‐SR cells. PTOV1‐AS1 knockdown repressed the proliferation, invasion, and drug resistance of sorafenib‐resistant HCC cells by targeting the expression of miR‐505. In conclusion, the expression of PTOV1‐AS1 is increased in HCC and sorafenib‐resistance HCC cells, as well as is associated with patients' prognosis. Inhibition of PTOV1‐AS1 expression can reduce the resistance of sorafenib‐resistant HCC cells, which may play a role by targeting the negative regulation of miR‐505 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, 900TH Hospital of Joint Logistics Support Force, Fuzhou, China.
Förderung
- Special Cultivation Fund for Outstanding Youth of the 900TH Hospital of Joint Logistics Support Force
- Fujian Natural Science Foundation Project (General)
Zitieren
APA
Chi, X., Chen, Z., Chen, Y., Hong, H., Yu, J., & Lv, L. (2023). Upregulation of lncRNA PTOV1‐AS1 in hepatocellular carcinoma contributes to disease progression and sorafenib resistance through regulating miR‐505. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.23437
Vancouver
Chi X, Chen Z, Chen Y, Hong H, Yu J, Lv L. Upregulation of lncRNA PTOV1‐AS1 in hepatocellular carcinoma contributes to disease progression and sorafenib resistance through regulating miR‐505. Journal of Biochemical and Molecular Toxicology. 2023. doi:10.1002/jbt.23437
BibTeX
@article{Chi2023,
author = {Chi, Xiaobin and Chen, Zhijian and Chen, Yongbiao and Hong, Hanyin and Yu, Jianda and Lv, Lizhi},
title = {Upregulation of lncRNA PTOV1‐AS1 in hepatocellular carcinoma contributes to disease progression and sorafenib resistance through regulating miR‐505},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2023},
doi = {10.1002/jbt.23437}
}
EUVIMED